Latest acute lymphoblastic leukemia Stories
CAMBRIDGE, Mass., April 18, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has signed an agreement with Abbott, a global healthcare company, to develop a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676, Epizyme's most advanced clinical product candidate, is an inhibitor targeting the DOT1L histone...
ACGT today announced that seed money provided for innovative T-Cell immunotherapy cell and gene therapy research has led to two successful Clinical Trials for treatment of Acute Lymphoblastic Leukemia resulting in remissions in both children and adults who had no other hope of recovery. Stamford, Connecticut (PRWEB) April 08, 2013 Alliance for Cancer Gene Therapy, Inc. (ACGT), http://www.acgtfoundation.org, https://twitter.com/acgtfoundation, and https://www.facebook.com/acgtfoundation,...
WHITE PLAINS, N.Y., April 4, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency funding many of today's breakthroughs in blood cancer treatments, including advances in targeted therapies, immunotherapies and epigenetics. Many LLS-funded researchers will be presenting results of some of their latest work at the 104(th) AACR Annual Meeting 2013, taking place at the Walter E. Washington Convention Center in Washington. D.C.,...
redOrbit Staff & Wire Reports - Your Universe Online A research team from The Children's Hospital of Philadelphia and the University of Pennsylvania used a novel cell therapy to reprogram the immune cells of two leukemia patients, resulting in a complete remission of the disease and a total lack of evidence of cancer cells in their bodies. The treatment, which is described in a study that is currently available online and will appear in the April 18 print edition of the New England...
-- CHOP/Penn Medicine Oncology Team Reports Complete Remission in Pediatric ALL Patients PHILADELPHIA, March 25, 2013 /PRNewswire-USNewswire/ -- Two children with an aggressive form of childhood leukemia had a complete remission of their disease--showing no evidence of cancer cells in their bodies--after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells. A research team from The Children's Hospital of...
Brett Smith for redOrbit.com - Your Universe Online Job training can allow workers to take on new responsibilities and a team of oncologists from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York found that the same thing applies to the body’s immune system. By essentially taking T cells, a type of white blood cell, back to school – the oncologists were able to successfully eradicate a certain type of acute leukemia. Similar previous research has shown promise in young...
St. Jude Children's Research Hospital-led study links inherited variations in a few genes to a substantially increased risk of acute lymphoblastic leukemia and helps to explain ethnic differences in the cancer's incidence MEMPHIS, Tenn., March 19, 2013 /PRNewswire-USNewswire/ -- Humans have between 20,000 and 25,000 genes that carry instructions for assembling the proteins that do the work of cells. Work led by St. Jude Children's Research Hospital found that children who inherit...
Griffith University researchers find cancer cell weakness Scientists at Griffith University's Institute for Glycomics and The Saban Research Institute of Children's Hospital Los Angeles have discovered a critical weakness in leukaemic cells, which may pave the way to new treatments. The research team has demonstrated that leukaemic cells can be eradicated by removing a carbohydrate modification displayed on the cell's surface. Director of Griffith University's Institute for...
An international study coordinated at the IRCM finds a possible alternative treatment to significantly reduce the adverse effects of chemotherapy An international research team coordinated at the IRCM in Montréal found a possible alternative treatment for lymphoid leukemia. Led by Dr. Tarik Möröy, the IRCM’s President and Scientific Director, the team discovered a molecule that represents the disease’s “Achilles’ heel” and could be targeted to develop a new approach that would...
Finding emerged from 100 billion RNA nucleotides in 10 children with cancer After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer—the first time anyone has linked the disease's reemergence to specific genetic anomalies. The discovery, co-lead by William L. Carroll, MD, director of NYU Langone Medical Center's Cancer Institute, is reported in a study...
